Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of CellSource Co., Ltd.. A complete text table follows the diagram.
The company generated ¥1.78bn without a disclosed product or customer mix.
Swipe to explore
Every category amount is a reported EDINET XBRL fact. Nodes described as arithmetic bridges are calculated residuals and do not imply a separately reported filing line.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Reported life-science sales | 1 | 1.8B | 100.0% of reported total |
| Cell-analysis and life-science products | 2 | 1.8B | Reported six-month total · ¥1.8B |
| Operating profit | 3 | 126M | 7.1% operating margin |
| Operating costs & expenses | 3 | 1.6B | Arithmetic residual to reported operating profit |
| Profit before tax | 4 | 108M | Reported pretax result |
| CellSource is building a life-science platform around cell analysis | 4 | 17.4M | Sales reached ¥1.78bn with ¥1.04bn gross profit; listing and store-closure costs remain separate. |
| Net profit attributable to owners | 5 | 71.2M | Reported parent-company result |
| Tax, attribution & other | 5 | 37.1M | Arithmetic bridge to owners' profit |
| From | To | Value |
|---|---|---|
| Reported life-science sales | Cell-analysis and life-science products | 1.8B |
| Cell-analysis and life-science products | Operating profit | 126M |
| Cell-analysis and life-science products | Operating costs & expenses | 1.6B |
| Operating profit | Profit before tax | 108M |
| Operating profit | CellSource is building a life-science platform around cell analysis | 17.4M |
| Profit before tax | Net profit attributable to owners | 71.2M |
| Profit before tax | Tax, attribution & other | 37.1M |